CCP
ATXS

Corient Capital Partners’s Astria Therapeutics ATXS Stock Holding History

Corient Capital Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,222
Closed -$117K – 696
2021
Q2 		$117K Sell
9,222
-8,032
-47% -$104K 0.01% 659
2021
Q1 		$299K Buy
+17,254
New +$312K 0.03% 448

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Corient Capital Partners's ATXS Position: Q3 2021 in Review

Corient Capital Partners sold out of Astria Therapeutics (ATXS) in Q3 2021, closing a stake of 9,222 shares — an estimated $117K sold.

Corient Capital Partners first reported a position in ATXS in Q1 2021 and held it in 2 quarters. The position peaked at $299K in Q1 2021. 35 funds tracked by Wall St. Rank hold ATXS as of Q3 2021.

  • Corient Capital Partners reported no remaining Astria Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Corient Capital Partners sold 9,222 Astria Therapeutics shares in Q3 2021, an estimated $117K.
  • Corient Capital Partners first reported a position in Astria Therapeutics in Q1 2021 and held it in 2 quarters.
  • Corient Capital Partners's Astria Therapeutics position peaked at $299K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2021.

Based on Corient Capital Partners's 13F filing for Q3 2021, filed 16 Nov 2021.